Carbon6 is a provider of a comprehensive software suite designed for online entrepreneurs operating within the Amazon marketplace. The company focuses on simplifying e-commerce business management by offering tools for business intelligence, inventory management, and advertising solutions. In addition to its software offerings, Carbon6 also acquires, develops, and integrates various technologies that support e-commerce merchants, enhancing their operational success. The company further supports entrepreneurs by providing educational programs, research tools, and resources aimed at improving product listings and overall profitability. Through its integrated solutions, Carbon6 aims to enable e-commerce businesses to achieve their goals and foster growth throughout their entrepreneurial journey.
TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, that specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. Founded in 2012, the company offers a range of products under the OviTex brand, including OviTex Reinforced Tissue Matrix for hernia repair and abdominal wall reconstruction, as well as OviTex PRS Reinforced Tissue Matrix for plastic and reconstructive surgery. Additionally, TELA Bio provides OviTex products specifically designed for laparoscopic and robotic surgical procedures, which utilize a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber. The company's marketing efforts are primarily conducted through a direct sales force operating mainly in the United States.
Forge Biologics, Inc. is a contract development and manufacturing organization based in Columbus, Ohio, focused on developing and manufacturing gene therapies and genetic medicines. The company specializes in viral vector gene therapies aimed at treating genetic diseases, including a novel approach combining adeno-associated virus (AAV) with umbilical cord transplants for infantile Krabbe disease, a severe neurodegenerative condition. Founded in 2019, Forge Biologics partners with scientists, healthcare professionals, and biotech and pharmaceutical companies to facilitate the transition of gene therapy programs from preclinical development to clinical and commercial-scale production. By providing end-to-end capabilities, the company aims to accelerate the availability of transformative medicines for patients suffering from rare genetic disorders.
Aterian is the leading consumer product platform. We build, acquire, and partner with brands, harnessing proprietary software and an agile supply chain to create top-selling consumer products.
Upstack is a SaaS-enabled marketplace based in New York City that transforms the procurement of colocation and network services for IT professionals, sellers, and consultants. Founded in 2017, the company aims to enhance transparency in the evaluation process by standardizing requests for quotes (RFQs), automating pricing, and providing analytics tools. Upstack facilitates optimal IT deployments by offering enterprise-grade pricing across a range of project sizes, from single server racks to large-scale colocation needs. Additionally, Upstack connects businesses with freelance graphic designers, enabling users to post project requests and receive proposals from pre-approved professionals. This dual focus on IT services and graphic design positions Upstack as a versatile platform catering to diverse business needs.
Unchained Labs is a developer of life science biologics tools designed to help researchers break free from tools that just don't cut it. It offers a multiplex protein stability platform for biologics that measures a host of protein stability parameters. The company's products include protein sizing systems, stability quantifiers, benchtop workflow solutions, automated buffer exchanges, concentration liberators, particle identifiers, and more, enabling biologics researchers to speed up their work with ease.
Unchained Labs was established in 2013 and is based in Pleasanton, California, USA.
Xtant Medical is a medical technology company specializing in the development, manufacturing, and marketing of regenerative medicine products and medical devices for orthopedic and neurological applications. The company offers a diverse portfolio of biomaterial products, including OsteoSponge, OsteoSelect DBM Putty, and OsteoWrap, which facilitate bone healing and fusion. Additionally, Xtant Medical provides a range of allografts designed for various surgical applications, such as anterior cruciate ligament repairs and spinal surgeries. The company's spinal implant systems support complex spine procedures and are utilized by orthopedic and neurosurgeons. Headquartered in Belgrade, Montana, Xtant Medical operates primarily in the United States and has established a significant presence in the orthopedic and neurosurgery markets through an extensive network of sales representatives and health system contracts. Formed through the merger of Bacterin International and X-spine Systems, Xtant Medical is positioned as a competitive player in the medical device industry, emphasizing innovation and comprehensive solutions for surgical needs.
LendingPoint LLC is a financial technology company based in Kennesaw, Georgia, founded in 2014. It specializes in providing online consumer loans through its cloud-based lending platform, which employs predictive risk algorithms to assess creditworthiness. LendingPoint offers personal loans for various purposes, including debt consolidation, home improvement, credit card refinancing, and medical expenses, among others. The company also operates LendingPoint Merchant Solutions, which provides financing options to merchants, service providers, and medical institutions. Committed to expanding access to fair financial solutions, LendingPoint delivers loans up to $25,000 with quick deposit options and no prepayment penalties, aiming to empower consumers to achieve their financial goals.
Medexus Pharmaceuticals is a specialty pharmaceutical company based in Chicago, dedicated to developing and commercializing innovative treatments for rare and orphan diseases. The company has a robust North American commercial platform and a diverse portfolio that includes products targeting various therapeutic areas such as hematology, rheumatology, oncology, auto-immune diseases, allergy, and pediatrics. By focusing on these specialized areas, Medexus aims to provide effective solutions for patients with complex health conditions.
Digital Reasoning Systems, Inc. specializes in developing data analytic solutions that process and organize unstructured data into meaningful insights. The company's flagship product, Synthesys, is an entity-oriented analytics software that automates the categorization, linking, retrieval, and profiling of unstructured data. It incorporates advanced features such as natural language processing, entity resolution, geo reasoning, temporal reasoning, and link analysis, while also providing visualization tools to illustrate connections within data sets. Digital Reasoning serves a diverse range of sectors, including government, legal, medical, and financial markets, and offers solutions tailored for intelligence analysts and cloud security. Founded in 2000 and headquartered in Franklin, Tennessee, the company maintains additional offices in New York City, Washington, D.C., and London, U.K. Digital Reasoning has established strategic partnerships to enhance its offerings and expand its reach in the marketplace.
Arboretum provides financing for fundamental capital assets which are business essential to middle market companies.
Protagonist Pty Ltd is a biotechnology company based in Brisbane, Australia, focused on developing innovative therapeutics for inflammatory and metabolic conditions. The company specializes in discovering peptide and small molecule compounds that mimic or inhibit protein-protein interactions relevant to therapeutic applications. Protagonist Pty Ltd also aims to identify drug candidates for targets that have traditionally been resistant to small molecule discovery, creating arrays of molecules that explore biologically-relevant chemical diversity. Originally founded as Cytokine Mimetics Pty Ltd in 2001, it operates as a subsidiary of Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops peptide-based products to address unmet medical needs, particularly in hematology and gastroenterology. Protagonist Therapeutics has a portfolio that includes drug candidates in various stages of clinical trials for conditions such as beta-thalassemia and inflammatory bowel disease.
Sight Sciences, Inc. is a medical device company specializing in ophthalmic technologies for the treatment of prevalent eye diseases, including glaucoma and dry eye conditions. The company offers the OMNI Surgical System, which allows for the performance of canaloplasty and trabeculotomy through a single device and incision, effectively targeting intraocular pressure in patients with primary open-angle glaucoma. Additionally, Sight Sciences provides the TearCare System, a software-controlled wearable technology that delivers targeted thermal energy to the meibomian glands, addressing issues related to meibomian gland dysfunction and dry eye. Founded in 2010 and headquartered in Menlo Park, California, Sight Sciences serves both ophthalmologists and optometrists with its innovative product offerings.
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Organogenesis is a regenerative medicine company specializing in the development, manufacture, and commercialization of advanced wound care and surgical solutions, primarily in the United States. The company's advanced wound care products include Apligraf, Dermagraft, and PuraPly AM, which are designed to treat various types of ulcers and wounds. In the surgical and sports medicine sector, its offerings include ReNu, NuCel, and additional products aimed at soft tissue repairs and bony fusion. Organogenesis also has a diverse pipeline of products, such as TransCyte for burns and Gintuit for mucogingival conditions. The company markets its solutions to hospitals, wound care centers, and physician offices through a combination of direct sales representatives and independent agencies. Founded in 1985 and headquartered in Canton, Massachusetts, Organogenesis has established itself as a pioneer in the regenerative medicine field, notably receiving the first FDA approval for a living, allogeneic cell-based product.
BioCryst Pharmaceuticals, Inc. is a biotechnology company that specializes in the discovery and development of oral, small-molecule medicines for rare diseases with significant unmet medical needs. The company’s approved products include RAPIVAB, an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, and ORLADEYO, an oral medication for preventing hereditary angioedema attacks in patients aged 12 and older. BioCryst is advancing several candidates in clinical trials, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, aimed at treating RNA viruses such as Ebola and Zika. The company engages in collaborations with various institutions, including government health agencies and pharmaceutical partners, to enhance its research and development efforts. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst Pharmaceuticals continues to focus on innovative therapies that address critical health challenges.
Sonar Entertainment is a independent entertainment studio that develops, produces, finances and distributes premium content for global audiences. It offer a unique platform for creative talent with the support of a full-service studio and global distribution company.
Kashable LLC is an online platform based in New York that provides employer-sponsored voluntary benefit programs focused on financial wellness. Established in 2013, the company allows eligible federal and company-sponsored employees to apply for low-cost loans online for various purposes, including managing costly debt and addressing unexpected expenses. The application process is streamlined, enabling users to receive an instant decision and have funds deposited directly into their bank accounts within three business days of approval. Repayment is facilitated through automatic payroll deductions, ensuring a convenient and structured approach to loan repayment. Kashable positions itself as a socially responsible credit provider, aiming to offer accessible financing options to employees while promoting financial stability.
The Credit Junction, LLC is an asset-based lending platform that specializes in providing working capital, growth, and supply chain financing solutions to small and mid-size enterprises in the United States and Canada. Founded in 2014 and headquartered in New York, the company leverages technology and data intelligence alongside traditional asset-based credit metrics to streamline the lending process. It offers asset-based loans of up to $7.5 million, targeting growth-oriented suppliers, distributors, and manufacturers with revenues ranging from $5 million to $50 million. The Credit Junction also operates user-friendly online portals for borrowers and affiliates, allowing for efficient document submission and facilitating a smooth application, vetting, and approval process. The company has formed strategic partnerships with various organizations to enhance its offerings and reach.
ZPower, Inc. develops and produces rechargeable silver-zinc micro batteries primarily for use in hearing aids, medical devices, and portable electronics. Founded in 1996 and based in Camarillo, California, ZPower offers a range of products, including various models of rechargeable micro batteries and charging systems for hearing aids. The company aims to provide an advanced battery solution that enhances product development for manufacturers while delivering high performance and improved user experience for consumers. In March 2020, ZPower filed for reorganization under Chapter 11 in the U.S. Bankruptcy Court, indicating financial restructuring efforts.
Partner Therapeutics, Inc. is an oncology company based in Lexington, Massachusetts, focused on developing and commercializing approved and late-stage cancer therapies. The company aims to improve treatment outcomes and reduce healthcare costs by providing a range of cancer treatments, from primary therapies to supportive care. One of its key products is Leukine, which promotes the growth of white blood cells, enhancing patients' immune responses during cancer treatment. Formerly known as Partners Oncology, Inc., the company rebranded in November 2017. Partner Therapeutics serves as a vital link between researchers and healthcare professionals, facilitating the advancement of cancer therapies.
DNAnexus, Inc. specializes in cloud-based genome informatics and data management tools tailored for enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company provides a platform that facilitates the analysis of raw sequencing data, integrates genomic data with clinical information, and enhances collaboration among researchers. Key offerings include the MOSAIC Microbiome platform for microbiome research, DNAnexus Apollo for clinico-genomic data exploration, DNAnexus Titan for data analysis, and DNAnexus Portals, which create secure online workspaces for collaborative projects. Additionally, the Clinico-Genomic Data Solution aims to enhance disease-specific datasets through partnerships with healthcare providers, improving screening and treatment pathways for complex diseases. DNAnexus serves a diverse clientele, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.
Sarepta Therapeutics is a biopharmaceutical company that focuses on the discovery and development of precision genetic medicine to treat rare diseases. It specializes in gene therapy, RNA-targeted exon skipping, and gene editing. It was founded in 1980 and headquartered in Cambridge, Massachusetts.
Aziyo is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material.
Fundation Group LLC is a digital credit lending platform based in Reston, Virginia, that connects financial institutions with small businesses to facilitate access to working and growth capital. Founded in 2011, the company partners with a variety of banks and B2B vendors to enhance the credit delivery process through technology and advanced analytics. Fundation offers a range of services, including outsourced lending, referral programs, and point-of-sale financing solutions. Its platform is designed to simplify the borrowing experience and streamline loan and deposit origination workflows for small and medium-sized businesses. By focusing on innovation, Fundation aims to empower its partners to better serve their small business clients, thereby strengthening the small business economy.
Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed to replace the century old Mantoux skin test ( TST ).
BioCryst Pharmaceuticals, Inc. is a biotechnology company that specializes in the discovery and development of oral, small-molecule medicines for rare diseases with significant unmet medical needs. The company’s approved products include RAPIVAB, an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, and ORLADEYO, an oral medication for preventing hereditary angioedema attacks in patients aged 12 and older. BioCryst is advancing several candidates in clinical trials, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, aimed at treating RNA viruses such as Ebola and Zika. The company engages in collaborations with various institutions, including government health agencies and pharmaceutical partners, to enhance its research and development efforts. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst Pharmaceuticals continues to focus on innovative therapies that address critical health challenges.
Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic diseases that require long-term treatment. The company is known for its innovative Medici Drug Delivery System, which utilizes subcutaneous delivery methods to provide steady dosing of therapeutic agents, particularly for conditions such as type 2 diabetes and obesity. Its flagship product, ITCA 650, is currently in a phase 3 clinical program aimed at improving treatment outcomes for diabetes patients through a unique delivery mechanism. In addition to diabetes, Intarcia is engaged in research and development for therapies targeting autoimmune disorders and other chronic conditions. Founded in 1995 and headquartered in Boston, Massachusetts, Intarcia also has a manufacturing facility in Hayward, California, and a research center in Durham, North Carolina.
IOU Financial Inc., through its subsidiary IOU Central Inc., operates a commercial lending business in North America, specializing in providing capital to small businesses across various sectors including medical and dental practices, retail stores, restaurants, and manufacturing companies. Founded in 1977 and headquartered in Montreal, Canada, the company has funded over $200 million in small business loans, showcasing its extensive experience in the field. IOU Financial originates and services commercial loans, retaining a portfolio of loans receivable while also selling loans to third-party purchasers on a non-recourse basis. This approach allows the company to offer flexible lending solutions tailored to the growth opportunities of its diverse clientele.
Spectra7 Microsystems Inc. is an analog semiconductor company based in San Jose, California, with operations in Canada and China. The company focuses on providing high-performance solutions that enhance bandwidth, speed, and resolution for consumer electronics. Its product offerings include advanced technologies for virtual reality (VR) and augmented reality (AR), such as the VR7050, which supports lightweight interconnects for gesture recognition, and the AR-Connect, an integrated solution for AR vision systems. Additionally, Spectra7 develops high-bandwidth, low-latency products like DreamWeVR for VR headsets and AR glasses. The company also caters to data center needs with specialized interconnects and consumer interfaces like GaugeChanger and USB 3.1, suitable for ultra-thin laptops, tablets, and mobile devices. Through its innovations, Spectra7 Microsystems aims to facilitate disruptive designs in various connectivity markets.
Spectranetics Corporation specializes in the development, manufacturing, marketing, and distribution of single-use medical devices designed for minimally invasive procedures in cardiovascular health. The company’s product offerings include various devices for vascular intervention, such as laser and aspiration catheters, scoring balloon catheters, and drug-coated balloon catheters, aimed at addressing arterial blockages in the legs and heart. Additionally, Spectranetics provides advanced lead management solutions, including excimer laser sheaths and associated accessories for the removal of pacemaker and defibrillator leads. The Stellarex DCB platform is also part of their portfolio, specifically targeting peripheral arterial disease. Spectranetics sells its products directly and through distributors across multiple global regions, focusing on improving outcomes in challenging cardiovascular cases. Founded in 1984 and headquartered in Colorado Springs, the company is committed to innovation in medical technology to enhance the quality of care for patients undergoing cardiovascular procedures. As of August 2017, it operates as a subsidiary of Philips Holding USA Inc.
Flexion Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions. Based in Burlington, Massachusetts, it offers ZILRETTA, an intra-articular injection specifically designed for managing osteoarthritis pain in the knee. The company is also developing FX201, a gene therapy aimed at promoting the production of an anti-inflammatory protein for knee osteoarthritis pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Since its founding in 2007, Flexion Therapeutics has collaborated with pharmaceutical and biotechnology firms to advance its drug candidates through clinical trials, thereby enhancing the therapeutic portfolios of its partners.
Quotient Biodiagnostics specializes in the development and provision of high-quality immunohematology products for hospitals and blood banks in the United States. The company leverages over 30 years of expertise in research, development, and manufacturing through its wholly-owned subsidiary, Alba Bioscience. Quotient offers a range of transfusion diagnostics products that have been distributed globally, either directly or through partnerships with major transfusion companies. By focusing on the needs of healthcare institutions, Quotient aims to enhance the quality and reliability of blood transfusion practices.
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on developing and marketing pharmaceutical products for pain management and addiction medicine in the United States and internationally. The company utilizes its patented BioErodible MucoAdhesive (BEMA) technology, which consists of a small erodible polymer film designed for application to the buccal mucosa, to create effective drug delivery systems. Its product portfolio includes BELBUCA, a buprenorphine buccal film for chronic pain management; BUNAVAIL, a combination buccal film of buprenorphine and naloxone for treating opioid dependence; and ONSOLIS, a fentanyl buccal film for managing breakthrough pain in cancer patients. Additionally, BioDelivery Sciences offers Symproic, a medication for opioid-induced constipation in adults with chronic non-cancer pain. Founded in 1997 and headquartered in Raleigh, North Carolina, the company aims to address significant unmet medical needs in the therapeutic areas it serves.
Aventine Renewable Energy, Inc. is a producer of ethanol and related by-products. They market and distribute our ethanol and co-products to many of the leading energy and food companies located in the United States and around the world. They are proud to be one of the largest providers of renewable energy. The products we produce and sell help reduce our country's dependence on foreign oil, benefit the environment by reducing pollutants and improve automobile performance.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Omeros Corporation is a Seattle-based biopharmaceutical company engaged in the discovery, development, and commercialization of small-molecule and protein therapeutics. The company focuses on large-market and orphan indications, particularly targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. Omeros offers OMIDRIA, a product used during cataract surgery in the United States. Its clinical pipeline includes narsoplimab, a monoclonal antibody in Phase III trials for various conditions, including hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy. Other clinical programs involve treatments for opioid and nicotine addiction, as well as compulsive disorders. Preclinical efforts include developing therapies for paroxysmal nocturnal hemoglobinuria and exploring a range of G protein-coupled receptors for various disorders. Founded in 1994, Omeros is committed to addressing significant unmet medical needs through its innovative therapeutic approaches.
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Apollo Endosurgery is a medical technology company specializing in the design, development, and commercialization of devices aimed at enhancing gastrointestinal therapeutic endoscopy. Founded in 2005 and headquartered in Austin, Texas, the company offers a range of products, including the OverStitch Endoscopic Suturing System and the Orbera intragastric balloon system. These devices enable physicians to perform advanced endoscopic procedures, such as placing full-thickness sutures and reducing stomach capacity to aid in weight loss. Additionally, Apollo provides aftercare support through the Orbera Coach program. The company's products are utilized by gastroenterologists and bariatric surgeons across the United States, Brazil, Australia, and various European countries, addressing conditions like gastrointestinal perforations, chronic fistulas, and abnormal lesions. Apollo Endosurgery's innovations are rooted in collaboration with a network of leading gastroenterologists and surgeons who have sought to advance the field of therapeutic flexible endoscopy since 1998.
Quotient Biodiagnostics specializes in the development and provision of high-quality immunohematology products for hospitals and blood banks in the United States. The company leverages over 30 years of expertise in research, development, and manufacturing through its wholly-owned subsidiary, Alba Bioscience. Quotient offers a range of transfusion diagnostics products that have been distributed globally, either directly or through partnerships with major transfusion companies. By focusing on the needs of healthcare institutions, Quotient aims to enhance the quality and reliability of blood transfusion practices.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.